[1501]
Sequence and comparative structural analysis of the murine ...
[18,4 KB]
From [www.springerlink.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1502]
The major homology region of bovine leukaemia virus p24 is ...
[349,4 KB]
From [vir.sgmjournals.org] Last viewed: 13.07.2004
NICE Technology Appraisal 29
Fludarabine in chronic lymphocytic leukaemia
Product
Condition
To be used in:
Not to
be used
in:
Impact on the
NHS
Audit data
NICE
Review
date
Fludarabine Chronic
B
cell
lymphocytic
leukaemia
(CLL)
Second line therapy in patients who
have failed or are intolerant of first
line chemotherapy, where
combination therapy would be
considered with either
cyclophosphamide, doxorubicin,
vincristine and prednisolone (CHOP);
cyclophosphamide, doxorubicin and
prednisolone (CAP) or
cyclophosphamide, vincristine and
prednisolone (CVP)
Oral fludarabine should be used in
preference to intravenous where
possible
First
line
therapy
for CLL
Increased costs of
drug likely to be
offset by reduced ...
[1503]
Pseudohypoxaemia in a patient with acute leukaemia
[133,9 KB]
From [thorax.bmjjournals.com] Last viewed: 13.07.2004
NICE Technology Appraisal 29
Fludarabine in chronic lymphocytic leukaemia
Product
Condition
To be used in:
Not to
be used
in:
Impact on the
NHS
Audit data
NICE
Review
date
Fludarabine Chronic
B
cell
lymphocytic
leukaemia
(CLL)
Second line therapy in patients who
have failed or are intolerant of first
line chemotherapy, where
combination therapy would be
considered with either
cyclophosphamide, doxorubicin,
vincristine and prednisolone (CHOP);
cyclophosphamide, doxorubicin and
prednisolone (CAP) or
cyclophosphamide, vincristine and
prednisolone (CVP)
Oral fludarabine should be used in
preference to intravenous where
possible
First
line
therapy
for CLL
Increased costs of
drug likely to be
offset by reduced ...
[1504]
UKALL XII: MRC study for patients with acute lymphoblastic ...
From [www.wacn.org.uk] Last viewed: 13.07.2004
U
U K
K A
A L
L L
L X
X I I I I
Medical Research Council Trial for Adult Patients with Acute
Lymphoblastic Leukaemia Under 56 years of Age: UKALL XII
Principal Investigator : Dr. R Marcus & Dr. J Keidan
Study Objectives:
To investigate the role of bone marrow transplants in adults aged 15-
55 years with acute lymphoblastic leukaemia (ALL). The outcome of
treatment with allogenic transplantation will be compared with either
myeloablative chemoradiotherapy or intensive consolidation and
maintenance chemotherapy. Patients in whom the Philadelphia
chromosome is detected either cytogenetically or by molecular
biological methods will in addition be eligible to receive an allogenic
bone marrow transplant for a matched unrelated donor (MUD) and to
receive alpha-interferon drug maintenance.
Study Treatment:
NO COMPATIBLE ...
[1505]
Protein Phosphorylation in Leukaemia Cells: Expression Profiles ...
From [srs.uaeu.ac.ae] Last viewed: 13.07.2004
College of Medicine and Health Sciences
The Fourth Annual U.A.E. University Research Conference
MHS - 32
Protein Phosphorylation in Leukaemia Cells: Expression Profiles and
Cell Dynamics
Kate Hammond, Department of Biochemistry, E-mail: katehmnd@uaeu.ac.ae
M M Qureshi, Department of Biochemistry ,
U.A.E. University, Al-Ain, P.O. Box: 17555, U.A.E.
S Madjarevic, Department of Molecular Medicine and Haematology, University of the
Witwatersrand, South Africa
1. INTRODUCTION
The presence of phosphate in protein
molecules was known a century ago, but only in
recent years was its vital functional importance
recognized, and now more and more phosphate-
containing proteins, protein kinases and
phosphoprotein phosphatases continue to be
identified at an ever-increasing rate. Initially it was
thought that the only possible targets for
phosphorylation ...
[1506]
Medical treatment for chronic myeloid leukaemia (CML): average ...
From [209.31.166.232] Last viewed: 13.07.2004
Medical treatment for chronic myeloid leukaemia
(CML): average cost effectiveness ratios of first and
second line treatment.
OBJECTIVE: to determine the average cost-effectiveness ratios of interferon used first line and imatinib used second line in chronic
phase CML.
METHODS: A general cost effectiveness analysis was performed. Therefore, a model consisting of two phases is developed. In an eight
months induction phase (see figure 1) newly diagnosed patients are treated with 2 different doses of IFN and CML-patients refractory to
IFN are treated with imatinib. This phase is followed by a chronic treatment phase in which patients are treated according the result of
the induction phase. Response rates were derived from the imatinib registration study and the study by Liberato et al (JCO, 1997).
During the induction phase 2% of patients treated with imatinib were intolerant and 27.5% of patients treated with IFN. ...
Found 1506 documents
Page 51 of 51 Pages:
<< < 41 42 43 44 45 46 47 48 49 50 51 > >>
cancers
homepage
last week